.Nature Medication, Posted online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized period 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) procedure of patients with HER2+ sophisticated breast cancer and active or steady mind metastases showed regular intracranial task and also wide spread efficiency of T-DXd.